937266
NanoFabTx™ for gene delivery
Maleimide lipid mix
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352142
NACRES:
NA.21
Recommended Products
General description
Maleimide lipid mix for gene delivery and targeted delivery
The NanoFabTx™ gene delivery maleimide lipid mix is a ready-to-use nanoformulation lipid mixture for the synthesis of maleimide-functionalized lipid nanoparticles (LNPs).These lipid nanoparticles can be used for targeting and immunotherapy applications, and nucleic acid encapsulation.
This product is a curated lyophilized lipid mixture of rationally selected lipids in precise ratios that have been optimized to achieve a desired size range of lipid nanoparticles. Step-by-step protocols for the synthesis of maleimide-functionalized LNPs by microfluidics with the NanoFabTx™ microfluidic- nano device kit (Cat. No. 911593) or nanoprecipitiation are included.
Maleimide-functionalized LNPs are particularly advantageous for gene delivery because the maleimide functional group enables the conjugation of thiol-containing antibodies, proteins, aptamers, or other molecules to the lipid nanoparticle surface. This can be used for multi-targeting or multi-type cargo delivery to different cell types including immune cells, making it advantageous for many different therapuetic applications including mRNA vaccine delivery and oncology.
This product is a curated lyophilized lipid mixture of rationally selected lipids in precise ratios that have been optimized to achieve a desired size range of lipid nanoparticles. Step-by-step protocols for the synthesis of maleimide-functionalized LNPs by microfluidics with the NanoFabTx™ microfluidic- nano device kit (Cat. No. 911593) or nanoprecipitiation are included.
Maleimide-functionalized LNPs are particularly advantageous for gene delivery because the maleimide functional group enables the conjugation of thiol-containing antibodies, proteins, aptamers, or other molecules to the lipid nanoparticle surface. This can be used for multi-targeting or multi-type cargo delivery to different cell types including immune cells, making it advantageous for many different therapuetic applications including mRNA vaccine delivery and oncology.
Application
With the NanoFabTx™ gene delivery maleimide lipid mix, researchers can simplify their drug development workflow. The ready to use mix enables the screening of different drug modalities such as oligonucleotides, nucleic acids (mRNA, DNA, siRNA), and vaccines without the need to develop new drug delivery formulations from scratch, ultimately speeding up the time it takes for innovative therapeutics to go from the bench to the clinic. The maleimide-functionalized surface of the LNP can be used to conjugate to many different thiol-containing biomolecules for active targeting. This ready-to-use lipid mix can also be used to screen different targeting moieties to determine what works best for your therapuetic and application. In addition, the lipid mix has been carefully crafted for enhanced gene delivery.
Features and Benefits
- A ready-to-use nanoformulation lipid blend to synthesize Maleimide-functionalized lipid nanoparticles
- Step-by-step protocols developed and tested by our formulation scientists
- Flexible synthesis tool to create uniform and reproducible lipid nanoparticles
- Optimized to make lipid nanoparticles around 100 nm with low polydispersity
- Optimized lipid blend for thiol-containing protein or antibody conjugation
- Optimized lipid blend for Maleimide-functionalized lipid nanoparticles for mRNA encapsulation
Legal Information
Legal Information NanoFabTx is a trademark of Sigma-Aldrich Co. LLC
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC
related product
Product No.
Description
Pricing
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
István Tombácz et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 29(11), 3293-3304 (2021-06-07)
Nucleoside-modified messenger RNA (mRNA)-lipid nanoparticles (LNPs) are the basis for the first two EUA (Emergency Use Authorization) COVID-19 vaccines. The use of nucleoside-modified mRNA as a pharmacological agent opens immense opportunities for therapeutic, prophylactic and diagnostic molecular interventions. In particular
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
Tombacz I, et.al.
Molecular Therapy, 29(11), 3293-3304 (2021)
In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles
Fang-Yi S, et al.
Science advances, 8(8), eabm7950- eabm7950 (2022)
Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics
Dammes N, et al.
Nature Nanotechnology, 16(9), 1030-1038 (2021)
Targeted delivery of lipid nanoparticle to lymphatic endothelial cells via anti-podoplanin antibody
Sakurai Y, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society, 349, 379-387 (2022)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service